This site is intended for healthcare professionals

Zynquista filed with FDA for Type 2 diabetes plus heart failure risk.- Lexicon Pharmaceuticals

Read time: 1 mins
Published:1st Jan 2022
Lexicon Pharmaceuticals announced that it has submitted a New Drug Application to the FDA seeking approval for the marketing and sale of Zynquista (sotagliflozin) to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction.

The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

The NDA submission is supported by the results from the Phase III SOLOIST clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease.

Both SOLOIST and SCORED achieved their respective primary endpoints, with overall tolerability similar to placebo across both trials. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles.

Condition: Diabetes Type 2 + CV Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights